GDF ‐15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes
Liver International · 2026
DOI: 10.1111/liv.70516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2026. Verfasst von Benedikt Silvester Hofer und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Liver Cirrhosis, Bacterial Translocation, Growth Differentiation Factor 15. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ludwig Boltzmann Gesellschaft.
Abstract (Originalsprache)
Background &Aims Growth differentiation factor‐15 (GDF‐15), a cell stress‐induced cytokine, is implicated in liver disease pathophysiology. We investigated GDF‐15 in cirrhosis, focusing on its association with disease‐driving pathomechanisms, platelet function, hepatic decompensation, and mortality.
Methods
We included patients with cirrhosis undergoing hepatic venous pressure gradient (HVPG) measurement at the Vienna General Hospital. Platelet surface P‐selectin and glycoprotein IIb/IIIa (GPIIb/IIIa) expression after agonist stimulation were assessed by flow cytometry as platelet activation markers. GDF‐15 serum levels were quantified by electrochemiluminescence immunoassay.
Results
Among 106 patients (median age 55.1 years; 70.8% male), median GDF‐15 was 2880 (1850–4770) pg/mL. GDF‐15 correlated with hepatic dysfunction (MELD Spearman's ρ : 0.50; albumin ρ : −0.57), HVPG ( ρ : 0.47), systemic inflammation (C‐reactive protein ρ : 0.45; interleukin 6 [IL‐6] ρ : 0.55; procalcitonin ρ : 0.58), liver stiffness ( ρ : 0.67) and enhanced liver fibrosis test ( ρ : 0.64) (all p < 0.001). GDF‐15 was higher in patients with detectable bacterial DNA in blood (3520 vs. 2250 pg/mL; p < 0.001) and correlated with lipopolysaccharide ( ρ : 0.34; p = 0.010) and lipoteichoic acid ( ρ : 0.37; p = 0.004). Platelet activation was not linked to GDF‐15 after adjusting for liver disease severity, yet patients with undetectable GPIIb/IIIa activation after stimulation showed significantly higher GDF‐15. Over a median follow‐up of 51.5 (26.0–58.2) months, 38 patients decompensated and 21 died (61.9% liver‐related). GDF‐15 (aHR per 100 pg/mL: 1.015; 95% CI: 1.004–1.026; p = 0.007) predicted decompensation risk independently of HVPG, MELD, albumin and IL‐6. Similarly, GDF‐15 was associated with higher risk of all‐cause (HR: 1.019; 95% CI: 1.009–1.029; p < 0.001) and liver‐related mortality (HR: 1.019; 95% CI: 1.007–1.032; p = 0.002).
Conclusions
GDF‐15 is a promising biomarker in cirrhosis that reflects disease‐driving pathomechanisms and independently predicts decompensation and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Division of Gastroenterology and Hepatology, Department of Medicine III, Vienna Hepatic Hemodynamic Laboratory, Medical University of Vienna, Vienna, Austria.
- Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
- Clinical Research Group (CRG) MOTION, Medical University of Vienna, Vienna, Austria.
- Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences, Vienna, Austria.
ORCID-Profile: Benedikt Silvester Hofer, Lorenz Balcar, Georg Kramer, Benedikt Simbrunner, Christian Sebesta, Mathias Jachs, Lukas Hartl, Mattias Mandorfer, Thomas Reiberger
Förderung
- Ludwig Boltzmann Gesellschaft
Zitieren
APA
Hofer, B. S., Perkmann, T., Brusilovskaya, K., Balcar, L., Hintersteininger, M., Kramer, G., Simbrunner, B., Caparros, E., Francés, R., Eichelberger, B., Lee, S., Zinober, K., Bödendorfer, B., Radovanovic-Petrova, B., Thöne, P., Sebesta, C., Jachs, M., Hartl, L., Schwabl, P., …, & Gremmel, T. (2026). GDF ‐15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes. Liver International. https://doi.org/10.1111/liv.70516
Vancouver
Hofer BS, Perkmann T, Brusilovskaya K, Balcar L, Hintersteininger M, Kramer G, et al. GDF ‐15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes. Liver International. 2026. doi:10.1111/liv.70516
BibTeX
@article{Hofer2026,
author = {Hofer, Benedikt Silvester and Perkmann, Thomas and Brusilovskaya, Ksenia and Balcar, Lorenz and Hintersteininger, Marlene and Kramer, Georg and Simbrunner, Benedikt and Caparros, Esther and Francés, Rubén and Eichelberger, Beate and Lee, Silvia and Zinober, Kerstin and Bödendorfer, Benjamin and Radovanovic-Petrova, Borka and Thöne, Paul and Sebesta, Christian and Jachs, Mathias and Hartl, Lukas and Schwabl, Philipp and Mandorfer, Mattias and Panzer, Simon and Reiberger, Thomas and Gremmel, Thomas},
title = {GDF ‐15 Levels in Cirrhosis Are Linked to Hepatic Fibrogenesis, Bacterial Translocation, and Worse Clinical Outcomes},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70516}
}
EUVIMED